Panacea Global Inc. (PANG) 0.0834 $PANG Panacea
Post# of 273332
Posted On: 09/21/2016 1:05:04 AM
Panacea Global Inc. (PANG) 0.0834 $PANG
Panacea Global Attains the Option to Purchase Majority Rights to the HAAH-Based Blood Test for the U.S. Market
Marketwired - Wed May 27, 12:02PM CDT
Panacea Global, Inc. ("Panacea"
(OTCBB: PANG) a biotechnology company focused on the discovery, development and commercialization of diagnostic products for the management of cancer, has recently acquired an option to purchase majority stake of the company that owns the rights to the U.S. market for HAAH-based blood test originally developed by Panacea Pharmaceuticals, Inc.
Panacea Global Presents Its Cancer Diagnostic Technology at the World Cancer Congress in Melbourne, Australia
Marketwired - Fri Dec 05, 11:44AM CST
Panacea Global, Inc. ("Panacea" (OTCBB: PANG) a biotechnology company focused on the discovery, development and commercialization of diagnostic products for the management of cancer will present its diagnostics technology based on a novel biomarker during the World Cancer Congress organized by UICC this week in Melbourne, Australia.
Panacea Global Attains the Option to Purchase Majority Rights to the HAAH-Based Blood Test for the U.S. Market
Marketwired - Wed May 27, 12:02PM CDT
Panacea Global, Inc. ("Panacea"
(OTCBB: PANG) a biotechnology company focused on the discovery, development and commercialization of diagnostic products for the management of cancer, has recently acquired an option to purchase majority stake of the company that owns the rights to the U.S. market for HAAH-based blood test originally developed by Panacea Pharmaceuticals, Inc. Panacea Global Presents Its Cancer Diagnostic Technology at the World Cancer Congress in Melbourne, Australia
Marketwired - Fri Dec 05, 11:44AM CST
Panacea Global, Inc. ("Panacea"
(OTCBB: PANG) a biotechnology company focused on the discovery, development and commercialization of diagnostic products for the management of cancer will present its diagnostics technology based on a novel biomarker during the World Cancer Congress organized by UICC this week in Melbourne, Australia. 
(0)
(0)